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Research into mesenchymal stromal/stem cells (MSCs) has been particularly exciting in the past five years.
Our understanding ofmechanisms ofMSC-mediated tissue regeneration has undergone considerable evolu-
tion. Recent investigation of the primary in situ counterpart of cultured MSCs has led to fresh insights into
MSC physiology and its role in the immune system. At the same time, the clinical application of MSCs
continues to increase markedly. Taken together, a reappraisal of the definition of MSCs, a review of current
research directions, and a reassessment of the approach to clinical investigation are timely and prudent.Introduction
Few cell types have captivated so many biomedical researchers
over the last 10 years as have mesenchymal stromal/stem cells
(MSCs). PubMed, in 2012, identifies over 17,000 references for
‘‘mesenchymal stem cells’’ and more than 4,500 for ‘‘mesen-
chymal stromal cells.’’ There have been several comprehensive
recent reviews on MSCs (Uccelli et al., 2008; Bianco et al., 2008;
Tolar et al., 2010; Ranganath et al., 2012). Hence, rather than
cover all of the work in this field, in this perspective I will focus
on some areas that have seen notable advance in the past
5 years and others that warrant further investigation to improve
our insight into the properties and potential of this intriguing
cell population.
First, a case can be made to revisit the nomenclature and defi-
nition of MSCs, not as a semantic exercise, but to better define
the direction of research. The availability of new molecular tools
makes the need for rigorous definitions increasingly important.
Moreover, the differences between MSC populations derived
from different tissues are becoming more apparent, presenting
an additional challenge to devising a universal definition. MSCs
as currently defined are a phenomenon of in vitro culture,
suggesting that extrapolating the function of these cells to
activity in vivo must be done with caution. This limitation high-
lights the need for direct in vivo studies with endogenous
MSCs or an equivalent physiological population as an essential
next step in establishing their true biological role. It is encour-
aging in this regard that recent studies have employed trans-
genic animal models to enable the tracking and assessment of
MSC-like cells in vivo. The mechanisms underlying tissue regen-
eration and immune modulation by therapeutic doses of MSCs
also require further elucidation, particularly the extent to which
the two processes intersect. The more recent appreciation that
MSCs may not mediate tissue regeneration by direct cell
replacement is also likely to redirect investigation into more fruit-
ful directions. Finally, in view of the extraordinarily rapid and
extensive use of MSCs clinically, a reappraisal of the approach
to the development of clinical protocols based on confirmed
laboratory and preclinical observations would be timely and
helpful.
Background
MSCswere initially identified as a subpopulation of bonemarrow
cells with osteogenic potential as shown by heterotopic trans-plantation and subsequently were confirmed to contain clonal,
plastic adherent bone-marrow derived nonhematopoietic cells
in the mouse and guinea pig (Friedenstein et al., 1968, 1970,
1976). An in vitro colony assay developed by Friedenstein and
coworkers to detect the clonogenic cell among this population
(the colony-forming unit-fibroblast [CFU-F]) was also adapted
for human marrow (Castro-Malaspina et al., 1980). Subsequent
studies in the 1980s focused on the role of a similar population
of bone marrow stromal cells derived from the adherent layers
of long-term bone marrow cultures in supporting hematopoiesis
(Dexter et al., 1977, reviewed in Clark and Keating, 1995).
Caplan’s proposal that these cells were mesenchymal ‘‘stem’’
cells (Caplan, 1991) capable of differentiation to all cells of
mesodermal lineage stimulated investigation into their role in
mediating tissue regeneration. Although the multilineage differ-
entiation potential of MSCs was later shown (Pittenger et al.,
1999), in vivo demonstration that these cells possess the hall-
mark stem cell characteristics of self-renewal and differentiation
had not been accomplished.
Confusion arising from the definition of the MSC population
made comparisons among published studies in the 1990s and
2000s problematic and led to the proposal of new terminology
and criteria by the International Society for Cellular Therapy
(ISCT) (Horwitz et al., 2005; Dominici et al., 2006). According to
these widely adopted proposals, the cells were more appropri-
ately considered mesenchymal stromal cells given that not all
were stem cells (Horwitz et al., 2005). The minimum criteria for
MSCs included plastic adherence and in vitro trilineage differen-
tiation to adipogenic, chondrogenic, and osteogenic cells
(Dominici et al., 2006). Additional requirements included cell
surface expression of CD105 (endoglin, SH2), CD73 (ecto-50-
nucleotidase), and CD90 (Thy1) and the absence of the hemato-
poietic markers, CD45, CD19, CD19 or CD79, CD14 or CD11b,
and HLA-DR. A particular challenge for the field has been the
absence of a specific marker to define MSCs, although a large
number of different determinants have been associated, albeit
not exclusively, with them (reviewed by Lindner et al., 2010
for human MSCs), including CD271 (low-affinity nerve growth
factor receptor) (Jones et al., 2002) and CD146 (Sacchetti
et al., 2007). MSCs are also highly activemetabolically, secreting
not only components of the extracellular matrix (Wight et al.,
1986) but also a vast array of cytokines (reviewed by Horwitz
and Dominici, 2008). More recent work has documentedCell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 709
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et al., 2012).
In addition to bonemarrow, MSC populations can be obtained
readily from adipose tissue (Zuk et al., 2002) and also from
a variety of tissues including placenta (In ’t Anker et al., 2004),
skin (Shih et al., 2005), umbilical cord blood (Erices et al.,
2000), umbilical cord perivascular cells (Sarugaser et al., 2005),
umbilical cord Wharton’s jelly (Wang et al., 2004), dental pulp
(Gronthos et al., 2000), amniotic fluid (Nadri and Soleimani,
2007), synovial membrane (De Bari et al., 2001), and breast
milk (Patki et al., 2010).
Revisiting the Definition of MSCs
The minimum criteria for defining MSCs established earlier
(Horwitz et al., 2005; Dominici et al., 2006) may now be unduly
constraining for a number of reasons. First, the characteristics
of MSCs may vary according to the source of tissue. In an effort
to define an MSC-like product, scientific entrepreneurs and
biotechnology companies have focused on differences in
surface marker profile to optimize intellectual property protec-
tion of relatively similar cell types. The recognition of species-
specific differences in cell characteristics and generation of
a variety of transcriptional and secretomic signatures for the cells
also indicate diversity. Moreover, panels of reagents (especially
antibodies) equivalent to those available for characterizing
human MSCs are still not in place for a number of other species,
so the criteria recommended by the ISCT (Dominici et al., 2006)
may be difficult to meet.
The challenge is to devise an appropriate definition without
losing the benefit that the current criteria provide in enabling
evaluation of different studies of similar, if not identical, cell
populations. A major hurdle is the absence of a single character-
istic or marker with which to define MSCs. Nonetheless,
a re-evaluation is timely and will require consensus among
leading investigators in the field. In addition to standard
methods of cell characterization of which surface marker profile
and differentiation potential are the mainstays, the relative
benefits of more advanced molecular tools including assess-
ments of the cell transcriptome, proteome, and secretome
(Ranganath et al., 2012) should be evaluated in creating this
new definition. Moreover, the need to demonstrate trilineage
differentiation, especially toward the chondrogenic lineage by
MSCs derived from tissues other than bone marrow, also
requires reassessment.
It is possible that a global definition of MSCs may now be
overly simplistic or unnecessary. Specific definitions of particular
MSC subsets may suffice, provided that they accurately and
reproducibly define the cells under study. For example, the so-
called stromal vascular fraction (SVF) of adipose-derived cells
represents a highly heterogenous cell population and contains
cells that express CD90 but not CD105 until they become plastic
adherent (Yoshimura et al., 2006). Nonetheless, the cells have
been considered to be MSC like. This issue is of additional
significance because SVF cells have been extensively applied
in clinical settings, despite a paucity of reported trials. It is
unclear whether these cell products are uniformly defined prior
to clinical administration.
Some general concepts of a new approach to the nomencla-
ture, definition, and characterization of MSCs may provide710 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.a framework for discussion. The rationale is to help inform the
investigation of these cells rather than to serve merely as a clas-
sification:
(1) The general population of MSCs should continue to be
identified as mesenchymal stromal cells, although this is
not an ideal term.
(2) The term ‘‘mesenchymal stem cell’’ should be used to
specifically describe a cell with documented self-renewal
and differentiation characteristics.
(3) MSCs should be categorized as cultured or primary—this
is an important distinction (see below) because the
characteristics are likely to be different and should avoid
confusion when comparisons are made between studies.
(4) The source of MSCs should be specified (e.g., adipose,
BM, cord blood, etc.); differences in cell characteristics
are likely to be encountered.
(5) Species should be identified—this information is not
always explicitly stated in the text of publications (except
in the Methods section) and has led to confusion in the
past.
(6) Minimum criteria for a surface marker profile need to be
revisited and are likely to vary among species.
(7) The need to document the in vitro differentiation potential
of the cells should be re-examined.
(8) The in vitro clonogenic capacity of MSCs should be
enumerated.
(9) The reproducible representation of transcriptome, pro-
teome, and secretome of MSCs should be evaluated
and the major factors influencing the signatures should
be identified and specified.
(10) Consideration should be given to characterizing the cells
according to tissue specificity (e.g., the differentiation
potential of human umbilical cord perivascular cells is
more extensive than for BM MSCs).Stem Cell Properties of Cultured MSCs
Despite numerous reviews attesting to the stem cell nature of
MSCs from their ability to undergo differentiation along at least
three lineages, there appear to be only three studies that can
lay claim to identifying stem cells among human cultured
MSCs, on the basis of rigorous clonal analysis. Muraglia et al.
(2000) showed by limiting cell dilution that clones arising from
single cells of bone marrow stromal cultures displayed multiline-
age differentiation potential and exhibited self-renewal. These
authors proposed a hierarchical model in which there was
sequential loss of lineage potential from the most primitive
osteo-chondroadipogenic to osteo-chondrogenic, and finally
to osteogenic precursors. Notably, osteo-adipogenic and chon-
dro-adipogenic precusors were not detected, nor were purely
chondrogenic or adipogenic clones. Lee et al. (2010) conducted
single-cell studies of GFP-marked human MSCs (using irradi-
ated stromal feeder layers to facilitate growth) and demonstrated
that a minor subpopulation with high proliferative potential
exhibited differentiation along osteogenic, chondrogenic, and
adipogenic lineages and could self-renew from colony replating
assays.
Analyzing the clonogenic differentiation capacity of another
MSC population, human umbilical cord perivascular cells
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renewal and multipotent capacity of an infrequent mesenchymal
stem cell able to differentiate to myogenic, osteogenic, chondro-
genic, adipogenic, and fibroblastic lineages and proposed a
hierarchical stem cell lineage relationship for these cells. These
examples highlight the differences in differentiation potential
between cells obtained from different tissues. This is an impor-
tant area of investigation because as in the case of hematopoi-
etic stem cell lineage relationships, much can be learned from
studies of MSC clones that may be lost by an investigation of
a heterogeneous MSC population, even one enriched for clono-
genic cells.
Immunomodulatory Properties of Cultured MSCs
At this point, there is a considerable body of literature document-
ing the pleotropic effects of MSCs on the immune system. MSCs
act on both the adaptive and innate immune systems by sup-
pressing T cells, suppressing dendritic cell maturation, reducing
B cell activation and proliferation, inhibiting proliferation and
cytotoxicity of NK cells, and promoting the generation of
regulatory T cells via an IL-10 mechanism. The role of MSCs in
mediating these processes by affecting the expression of
inflammatory cytokines is well established. This topic has been
covered extensively in several reviews (Nauta and Fibbe, 2007;
Le Blanc and Ringde´n, 2007; Uccelli et al., 2008; Tolar et al.,
2010; Chen et al., 2011, among others), and I will therefore focus
on drawing attention to a few key issues.
Onemajor area of MSC-mediated activity is T cell suppression
(Yang et al., 2009). Several recent studies have identified path-
ways that are involved, including downregulation of NF-kB
signaling and cell cycle arrest at G0/G1 (Jones et al., 2007;
Choi et al., 2011). However, it is still somewhat unclear to what
extent these pathways will have physiological significance.
Some of the confusion in the literature in this area may be allevi-
ated by the appreciation that there are major differences in the
mechanisms of T cell suppression among species. For example,
in humans and Rhesus monkeys, indoleamine 2,3- dioxygenase
(IDO) is predominantly involved in T cell suppression, whereas ni-
tric oxide is themainmediator inmice (Ren et al., 2008; Ren et al.,
2009).
One emerging area of investigation involves studies of Toll-like
receptors (TLRs) on MSCs and their contribution to immune
modulation. These receptors respond to so-called danger
signals consisting of molecules released by injured tissue or
microbial invasion (e.g., endotoxin, LPS, dsRNA, and heat
shock proteins). At least ten human TLRs are known and are
expressed on innate immune effector cells (Kawai and Akira,
2011). Surprisingly, functional TLR3 and TLR4 are abundantly
expressed on human BM-derived MSCs. Ligation of these
TLRs induces activation of proinflammatory signals and prevents
the suppression of T cell proliferation, possibly by MSC-medi-
ated downregulation of Notch ligand (Liotta et al., 2008;
Tomchuck et al., 2008). MSC-associated TLR signaling appears
to not only involve a direct immune stress response but also the
promotion of MSC migration (with TLR3 ligation). Interestingly,
TLR3 and TLR4 stimulation does not appear to suppress IDO
activity or PGE2 levels that decrease inflammatory responses
(Liotta et al., 2008) and raises important implications for the
role of MSCs in host defense. These observations suggest thatactivation of the TLRs on MSCs may maintain antiviral host
defense.
TLR-mediated proinflammatory responses by MSCs could
potentially have additional functional implications. On the basis
of the divergent patterns of TLR3 versus TLR4 ligation in
a short-term assay with respect to cytokine and chemokine
secretion, cell migration capabilities, TGF-b secretion, and
expression of the downstream effectors, SMAD3/SMAD7,
Waterman et al. (2010) proposed a novel paradigm for MSC
action. In their model, MSCs can polarize to a proinflammatory
MSC1 type (TLR4-primed) or an immunosuppressive MSC2
(TLR3-primed) phenotype, analogous to the action of M1 versus
M2 monocyte/macrophages (Dayan et al., 2011). Thus, the clas-
sical monocyte/macrophage responses to injury are reprised
with the MSC1 (response to acute injury)/MSC2 (anti-inflamma-
tory/healing) model (Figure 1).
It is also possible that through TLR signaling, MSCs play
a pivotal role in both initiating the clearance of pathogens and
promoting the repair of injured tissue, raising the possibility
thatMSCs could be employed clinically to augment host defense
(Auletta et al., 2012). For future applications, the challenge will be
to discover the key factors that contribute to achieving a balance
that functions effectively in the best interests of the host. The
next steps include confirmatory studies using different assays
for further testing in animal models. In that regard, investigators
will need to deal with the additional level of complexity from
MSC-mediated augmentation of IL-10 production by macro-
phages via TLR4 ligation (Ne´meth et al., 2009).
As is true for most studies of MSCs, the bulk of these immune
modulation experiments were conducted with cultured MSCs.
Data generated in vivo from putatively equivalent primary
MSCs (MSCs in situ) remain lacking. Unfortunately, an assess-
ment of immune interactions of uncultured MSCs in vivo has
the same limitations as those for other MSC studies: the low
frequency of primary MSCs in vivo, a lack of appropriate animal
models, and interspecies variation in mechanisms of action (Ren
et al., 2009). Differing results may also be reconciled by taking
into account opposing mechanisms tomaintain immune homeo-
stasis. Alternative explanations include differences in cell dose,
assay methodology, and MSC source. Given these limitations,
an attempt to extrapolate in vitro data by Uccelli et al. (2008) is
laudable and possibly amenable to testing. These authors
provide several intriguing potential explanations for effects
in vivo. For example, the effect of infused cultured MSCs on
NK and dendritic cells may result in potentially opposite interac-
tions that eventually will be resolved by predominant microenvi-
ronmental cytokine levels.
Evolving Concepts of Tissue Regeneration by MSCs
Over the past decade, there has been considerable evolution in
our understanding of themechanisms underlying tissue regener-
ation from MSCs. Progress may have been limited to some
extent by the concept of the mesenchymal ‘‘stem’’ cell and the
implicit idea that the objective was cell ‘‘replacement’’ therapy.
For example, the concept of transdifferentiation of hematopoi-
etic progenitors into cardiac cells was difficult to dislodge,
despite rigorous studies failing to support the idea (Murry
et al., 2004; Balsamet al., 2004). It was interesting that this notion
was displaced by the phenomenon of cell fusion, anotherCell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 711
Figure 1. Proposed Immunomodulatory Mechanisms of Cultured MSCs
MSC-mediated immune interactions shown here include a proposed polarization of MSCs into MSC1 and MSC2 cells as a result of activation of Toll-like
receptors (based onwork byWaterman et al., 2010). Activation of MSC-resident TLR4 leads to aMSC1 orM1 type cell with a proinflammatory response, whereas
activation of TLR3 gives rise to aM2 typeMSCwith an anti-inflammatory/immunosuppressive response. Overall outcomewill depend on the balance between the
cytokines/chemokines released into the microenvironment.
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improvements in preclinical models of cell treatment of injured
tissue (if only because of its very low frequency).
However, the possibility that partial cellular reprogramming,
leading to the acquisition of some characteristics of the desired
lineage, could contribute to the tissue regeneration capacity of
MSCs (Rose et al., 2008) remains to be investigated. A recent
example of high throughput screening using human MSCs to
identify small molecules that promote chondrogenic differentia-
tion suggests an approach that may be more fruitful (Johnson
et al., 2012). These investigators showed that the small molecule
kartogenin induces chondrocyte differentiation of MSCs,
protects articular cartilage in vitro, and promotes cartilage repair
after intra-articular injection in an osteoarthritis animal model.
Whether the administration of exogenous MSC-derived chron-
drocytic cells will be superior to local treatment with the hetero-
cyclic molecule alone is not yet known. Nonetheless, a more
extensive drug discovery approach to identify molecules that
mediate the differentiation/reprogramming of MSCs along
mesodermal lineages is an exciting prospect.
Other explanations for the varying degrees of efficacy medi-
ated by MSCs have been extensively reviewed elsewhere and
are often characterized as ‘‘paracrine’’ effects. The cells are
perceived to exert their effects by the release of factors that
stimulate tissue recovery on many potential levels, including
stimulation of endogenous stem/progenitor cells, suppression
of apoptosis of vulnerable cells, remodeling of extracellular
matrix, and stimulation of new blood vessel formation. Investi-
gating MSCs as cytokine ‘‘factories’’ will likely uncover new
mechanisms and identify compounds that may in some cases
supplant the cells themselves (Ranganath et al., 2012). For
example, tumor necrosis factor-inducible gene 6 protein
(TSG6) is an immunosuppressive molecule produced by MSCs712 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.that partially recapitulates the hemodynamic improvement after
intravenous infusion of the cells following experimental acute
myocardial infarction in mice (Lee et al., 2009). This study serves
to further underscore the shift toward the importance of the
immunomodulatory properties of MSCs in regenerating injured
tissue. Another example is the association between cardiac
improvement and an MSC-mediated switch in macrophages/
monocytes infiltrating ischemic tissue from the M1 to M2 pheno-
type (Dayan et al., 2011). Of interest, the switch was observed
among circulatingmonocytes but not in the bonemarrow, raising
the possibility of a potentially useful distinction between more
commonly accepted paracrine phenomena versus an allocrine
effect produced by exogenous cells in a remote location.
How MSCs communicate with endogenous cells requires
further study and the contribution by which cell-cell contact
mediates the biological effects needs further clarification. In
this regard, exploring the role of exosomes, secreted vesicles
potentially involved in intercellular communication may provide
novel insights (Lai et al., 2011).
Physiological Role of Primary In Situ MSCs
The study of culture-expandedMSCs is unlikely to help establish
the physiological role of native in vivo cells. Progress in dealing
with this limitation has initially been slow, partly because poten-
tially useful experimental tools have been employed only recently
and the frequency of putative native MSCs is very low. However,
momentum is growing as the importance of these studies
becomes more evident.
McGonagle and others have shown that the in vivo counter-
part of MSCs has the following immunophenotype: CD45 or
low, CD271+ (Jones et al., 2002). More recent data show that
the cells within this population have greater transcriptional
activity than cultured MSCs or dermal fibroblasts, reflecting
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transcription of osteogenic and Wnt-related genes (Churchman
et al., 2012). CD105+ cells can also be isolated in situ from human
bone marrow and exhibit high levels of CFU-F activity, generate
CD105+ CD90+, and CD106+ cells that undergo trilineage differ-
entiation (adipogenic, chondorgenic and osteogenic lineages)
after culture, and differentiate into osteoblasts in vivo in
response to BMP-2 (Aslan et al., 2006).
Other evidence indicates that the human in situ MSC in vivo is
CD146+, gives rise to CFU-F, and exhibits self-renewal in vivo.
These cells are also capable of forming both bone and hetero-
topic hematopoiesis-associated MSCs from single clones in
immune-deficient murine experiments. The CD146+CD45 cells
are subendothelial and localize in vivo as adventitial reticular
cells (Sacchetti et al., 2007). More recent work from another
group has confirmed that CFU-F activity resides exclusively
in the CD271+ cell population enriched directly from human
marrow cells and shown that both CD271+CD146+ or
CD271+CD146() cells can give rise to stromal clones that
form bone ossicles and hematopoiesis-associated stromal cells
(Tormin et al., 2011). The Frenette group has shown that a small
proportion of MSCs are Nestin+, can self-renew in vivo, contain
all the CFU-F activity of the bone marrow, and undergo
osteogenic, chondrogenic, and adipogenic differentiation
(Me´ndez-Ferrer et al., 2010). The relationship of these mesen-
chymal stem cells and CXCL12-abundant reticular (CAR) cells
(Sugiyama et al., 2006), which also have osteoprogenitor
capacity, requires further investigation. However, short-term
ablation of CAR cells in vivo impaired the ability of BM cells to
undergo adipogenic and osteogenic differentiation (Omatsu
et al., 2010). The Scadden group has further examined osteoline-
age progenitors in the MSC pool. Their recent elegant study of
bone maintenance and repair (Park et al., 2012) highlights the
importance of genetic tools that better define the in vivo role of
BM MSCs. They showed that a subset of Nestin+ osteoline-
age-restricted MSCs present in vivo are able to replace short-
lived mature osteoblasts to maintain homeostasis and respond
to bone injury (Park et al., 2012).
Taking an innovative approach involving phage display and
cell sorting, Daquinag et al. (2011) screened combinatorial
libraries for peptides that target adipose stromal cells in vivo
in the mouse based on the immunophenotype profile,
CD34+CD31CD45. They found a cell surface marker, the
N-terminally truncated proteoglycan, d-decorin highly ex-
pressed on the cells in vivo and identified resistin, a known
protein adipokine, as its endogenous ligand. They hypothesized
that signaling by resistin via the d-decorin receptor regulates the
fate of adipose stromal cells. Although observed almost in
passing, the authors note that the d-decorin is localized on the
cell surface that faces away from blood vessels, suggesting an
opportunity to interact with extracellular matrix components. In
addition, they found that culturing the stromal vascular fraction
(SVF) of adipose cells under standard conditions for generating
MSCs led to loss of cell surface d-decorin. These data under-
score the challenges associated with identifying unique cell
markers on cultured MSCs. Nonetheless, a similar approach
for identifying an analogous receptor/ligand on bone marrow-
derived MSCs may also yield valuable information regarding
the nature and biology of the native MSC in vivo.Clinical Application
At this point, there is extensive clinical activity involving MSCs,
and many available treatments are outside the oversight of
national regulatory bodies or clinical trial sites such as
ClinicalTrials.gov. Moreover, the outcomes of a large number
of these treatments are not documented in peer-reviewed
journals. Unfortunately, the rationale for the clinical application
of MSCs, particularly in regenerative medicine, has lagged
behind laboratory observations. It is important to optimize the
design ofMSC trials based on themost current preclinical obser-
vations to maximize their scientific rigor. Several protocols
involving systemic administration of MSCs to treat injured tissue
are still in progress because of the notion of cell replacement
therapy rather than on the more recently accepted paracrine
and anti-inflammatory effects of these cells. The study outcomes
are unlikely to be optimal if the major effect is actually an anti-
inflammatory one and may arise from number of factors
including inappropriate dose, scheduling, or route of administra-
tion. Furthermore, the coadministration of anti-inflammatory
agents may be a confounding factor.
A second issue is the difficulty in fully evaluating completed
clinical trials for which the results have not been formally pub-
lished in international peer-reviewed journals. Valuable insights
into trials design, patient selection, underlying rationale, and
potential improvements would be gained by rigorous peer
review.
Nevertheless, the results of several phase II trials with MSCs
show promise. Le Blanc’s phase II trial using MSCs to treat
steroid-resistant aGvHD (Le Blanc et al., 2008) indicates that
a multicenter randomized controlled trial should be conducted.
Because several transplant centers already routinely employ
MSCs for that indication on the basis of only the phase II data,
the need for a randomized controlled trial seems quite urgent.
MSCs were also tested for their ability to support kidney trans-
plantation on the basis of the promising data treating aGvHD. In
an open label prospective trial, 159 patients undergoing a living
related donor kidney transplant were registered for randomiza-
tion to receive IL-2 receptor antibody induction therapy versus
autologous BM-MSCs to assess rejection rate (Tan et al.,
2012). Although patient and graft survival were similar, patients
receiving MSCs had a lower incidence of acute rejection,
decreased probability of opportunistic infections, and better
kidney function 1 year later.
In addition, preclinical data have suggested that MSCs may
have a role in the management of acute myocardial infarction.
An industry-sponsored randomized double-blind placebo-
controlled dose escalation study of systemically administered
MSCs after acute myocardial infarction in 53 patients provided
safety and preliminary efficacy data (Hare et al., 2009). Adverse
events were similar between the test and placebo groups over
a 6 month period. Ventricular arrhythmias were reduced (p =
0.025) and pulmonary function improved (p = 0.003) in patients
receiving MSCs. In a subset analysis, patients with an anterior
acute myocardial infarct had improved ventricular function (ejec-
tion fraction) compared with the placebo cohort. These are
encouraging data and a prospective randomized trial with clini-
cally significant endpoints is awaited with interest.
Well-designed clinical trials will be critical for determining
whether MSCs can be effective in treating tissue injury orCell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 713
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tors work very closely with laboratory researchers to design
better clinical trials. Particular attention should be paid to factors
that may be overlooked but could affect the efficacy of MSCs,
including culture conditions/medium, oxygen tension, time
from thawing after cryopreservation to administration, the tissue
source of theMSCs, priming or activation prior to administration,
the use of gene engineered versus unmodified cells, MSC
subsets, and autologous versus allogeneic cells. Given the
serious limitations associated with testing human MSCs in
animal models, detailed analysis of immune and other perturba-
tions in patients participating in prospective trials should be
undertaken to help optimize subsequent protocols. Two other
areas also require further attention. The importance of cell
tracking and persistence of the exogenous MSCs in vivo in
affecting clinical outcome can only be addressed when the cells
are safely and effectively labeled and monitored. Although
several studies have looked at the persistence of MSCs in animal
models, similar correlative studies are required in human study
recipients. Currently, the only viable option is superparamag-
netic iron nanoparticles and magnetic resonance imaging,
but even this approach has very limited availability. Finally,
given the underreporting of MSC treatments and the paucity of
publications describing long-term follow-up after MSC adminis-
tration, a convincing case can be made for establishing a
database registry of cell therapy recipients to track treatment
outcomes and monitor for long-term adverse events. Two
additional aspects suggest that clinical correlative studies are
warranted. Although the recent observation of the acquisition
of chromosomal aberrations in cultured human adult stem
cells (Ben-David et al., 2011) is of uncertain significance
(Sensebe´ et al., 2012; Prockop and Keating, 2012), it will
be important to correlate assays of genetic instability prospec-
tively with clinical outcome. The other aspect relates to the
interaction of MSCs with cancer. Although there is a growing
body of literature in this area (Djouad et al., 2003), the
outcomes of experimental models appear to be conflicting.
A spectrum of responses has been observed with different
tumor models, from tumor suppression to stimulation. Clinical
correlation with studies of the signaling pathways involved in
stromal-tumor interactions is an important goal that should
also accompany the establishment of a cell therapy patient
registry.
Conclusions
In summary, the past 5 years have been remarkably active for
MSC studies. Several initiatives can be undertaken to further
accelerate the process of enhancing our understanding of
MSC biology and improve access to well-designed clinical trials.
Current definitions of this cell population need to be revisited
given the wide range of tissue sources and the recognition of
subpopulations with specific properties. Extending the avail-
ability of an international reference MSC repository for access
to all investigators is also a priority. Additional animal models
need to be developed to better identify and study the biology
of primary in situ MSCs. The design of optimal clinical trials
requires the close cooperation of laboratory and clinical investi-
gators. Future studies need to be designed that also include
assaying perturbations in patients in vivo and are therefore714 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.best positioned to overcome some of the inherent limitations of
xenogeneic animal models with human MSCs.
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